{"name":"Anika Therapeutics","slug":"anika","ticker":"ANIK","exchange":"NASDAQ","domain":"anika.com","description":"Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a hi","hq":"Bedford, MA","founded":0,"employees":"235","ceo":"Cheryl R. Blanchard","sector":"Regenerative Medicine / Orthopedics","stockPrice":15.35,"stockChange":0.43,"stockChangePercent":2.88,"marketCap":"$221M","metrics":{"revenue":112819000,"revenueGrowth":-5.9,"grossMargin":56.6,"rdSpend":25770000,"netIncome":-10880000,"cash":57481000,"dividendYield":0,"peRatio":38.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Monovisc patent cliff ($20.0M at risk)","drug":"Monovisc","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Orthovisc patent cliff ($15.0M at risk)","drug":"Orthovisc","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cingal","genericName":"Cingal","slug":"cingal","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Cingal","genericName":"Cingal","slug":"cingal","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Anika Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Anika Therapeutics reported fourth quarter and full year 2023 financial results, with revenue of $44.8 million and a net loss of $1.3 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Anika Therapeutics Announces Exclusive Distribution Agreement with Stryker for Hyalofast in the United States","summary":"Anika Therapeutics announced an exclusive distribution agreement with Stryker for Hyalofast in the United States.","drugName":"","sentiment":"positive"},{"date":"2023-08-16","type":"regulatory","headline":"Anika Therapeutics Receives FDA Clearance for Hyalofast in the United States","summary":"Anika Therapeutics received FDA clearance for Hyalofast in the United States.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaURWTGh2Q3IzdFBZTkdqS2g0VkhzZXdBdFFvNXQyVzU2aFBkZjBYakI1ZGpMTVliOXFzQkJHb1dPUWRjbTZjNWJlNm9ZVHlMUTdJYVpCRldFbi1kTEw3aEVkVGU0SngwOVhFMWl1Z1VOenVzbndpSzNIWWlfa1VZbkpaM0NDSzhjSkFXTEJzNFVFZm0yZm9fRUxpT2QwTTQ5Y2VLeUZDMmdwdk01MFJfTzVMZ19JZW8wYzdVTFR5Z0pUZk02RVU0TUtnbTV3eW5ldnVKWm9MamljQQ?oc=5","date":"2026-04-02","type":"pipeline","source":"MarketBeat","summary":"Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200 Day Moving Average - What's Next? - MarketBeat","headline":"Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200 Day Moving Average - What's Next?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQM1liWmJFRG1QNWh3VFNPZWEwd0l0M1NnS0tBNzQtSldMTDBfdy1nSEZpZXdsYi1TSl9FOWxneWZXeEhvbk1nUDBTajBEVWJZd1NEMXNHYUFhaVYtZFlmV1B0TmtEYjZObEN1UkNuZUk0amo0SUtKRWxuZ01RUVQtZTdvLXd4SmhWRGZJMWJTbFRadlhJTEJYd0tmdk15MGN0TTFXalAtdDJWMjJvVTAwNXZrMVptT00?oc=5","date":"2026-03-11","type":"pipeline","source":"Stock Titan","summary":"Anika Therapeutics (ANIK) director nets RSU shares after tax withholding - Stock Titan","headline":"Anika Therapeutics (ANIK) director nets RSU shares after tax withholding","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcjhXVmY0c0dpVGF2V3pNZU9LZnNWYkdlVy1FVExEWDJvRWV4bUE3TUlYeWhBcUpDZzkyN3lLal9QV25HOFdiOS1ONFFQcDlmVHQxemRyX0htUzBPaG1UN3AzOHQ5ajBOazJQMDViSEdnSDM0UjhZcG5xMExxbkVtQ1ZFRHBDbzc4OEFhblREVnhIRFJOUGdYczNVNU53SHdQZFNLUkJBUVk0b252eVpiNFVCaEtucFNMS0w1TGlWRDc?oc=5","date":"2026-02-04","type":"pipeline","source":"Stock Titan","summary":"Cancer imaging firm Lumicell taps 30-year biotech veteran Cheryl Blanchard for board - Stock Titan","headline":"Cancer imaging firm Lumicell taps 30-year biotech veteran Cheryl Blanchard for board","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQejF1bE5mZzZxek5kaVh6SHRwSV80RHdzakxoY2pOYVJGUkV6LUk0ai02S3dqX2lDc1UyYjEzbUhCQXBfQzktSDAyVGx4aHduUjRNMkVjbnVRcXFlT1lZUVZEZFlwN2lmZTZ4WmhVSGVQZ1UxSVNBUENvdF9RZlFZdElIQkkxZllpckRBM1I4NThrb1ZlWVVGLUVSY1U3Q3ljdVZQa05OZzhSS2g5czlpSGFnOXNVLUlQ?oc=5","date":"2025-12-23","type":"pipeline","source":"Trefis","summary":"How Low Can Anika Therapeutics Stock Really Go? - Trefis","headline":"How Low Can Anika Therapeutics Stock Really Go?","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQUVFZR29BVjFrYlRjWk9CRC1QX09wMnhfSlpkek1QNjdhb0hmMUg5b25FSXdrVDViNERWcWIxMFlfU1hUZV9WYks2ZE1jRnJmYkFqTVg4ODZySVdKOTczWGdPb0lJRklzVDNEa3drY3RTMUVteFczTHRzeTktMUdzWWJ6eGlyVTU1eVVGS2tuWHhjdWs3VVBQMVZrS1JtV0FzYkRIaC03QkRkc1d5c1E?oc=5","date":"2025-08-07","type":"pipeline","source":"Seeking Alpha","summary":"Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts (ANIK) - Seeking Alpha","headline":"Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts (ANIK)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-06","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive - simplywall.st","headline":"Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNdmVhRU5vZHFLWGkxV2JjUXBtV1FVVzFVdlFJSkhpaHBvSFN0TXRmLTdYdnhNbkE1d0FJaUxVLS1KYjhMWFVjZnJ2YWFaZ2pvVmlvNlk3R2R1aXk2dGdWRlBaYURGdW5KY2Yzdno0MkNmXy0yYmVHYkludFExVjJsS0hWWEM?oc=5","date":"2025-03-01","type":"deal","source":"Yahoo Finance","summary":"Is Anika Therapeutics, Inc. (ANIK) the Best Small Cap Pharma Stocks to Buy Now? - Yahoo Finance","headline":"Is Anika Therapeutics, Inc. (ANIK) the Best Small Cap Pharma Stocks to Buy Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPYjk5S3pRYW5xZUxXUGFZYnplemV6X201bWVCTldjTzJHcmJBYWhxS3dFZE5HSDhuWDF5Vll2eWRUN0ZjWGQzTTB1QzUyWWRhZndheGZXRVFGOFlnVUREdU1HNWxTbEpWek0wWDA2UkVPaUNnR1RRUEpzVzE0V2toZ0dlQm9rdW53YkxLMUxheFpaQS03TFVzXzVzZXFLWS1vbDZzajd3ZzgyMzdTQ0lTT0VLZkQxc0RSQm9DZTBnWDJuVWozQXByRGN3MTE2a1ky?oc=5","date":"2024-10-31","type":"pipeline","source":"PR Newswire","summary":"Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics - PR Newswire","headline":"Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9NVWpSaEh5d3pEcXhyWjhqejZXbzFIZk5VWjhPaExRTDJ1YS1UVEJFbmtGRU5WaElpTVpBcUYzdU9Gc2FiYVdZYWtEQ3FMd2JlU2xwTlAxdGs1SlNYRHBESzRzMl9obWN2TWluRTBkNkFvSVU?oc=5","date":"2023-08-18","type":"regulatory","source":"MassDevice","summary":"FDA clears rotator cuff repair implant from Anika Therapeutics - MassDevice","headline":"FDA clears rotator cuff repair implant from Anika Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNeWZ3X0VEVS1YelhKNm9xUUF6VWgxaDFNVFA0OEpmcndjVFBiX1FGbTFGTGk2QUhDaGkzdE1id2RtSF9Eak1nX3NNX2hJd29yN2pGcDVoTE1zeExfZW5IWGxnRHRBdUEtRFZtR1QyNDRKd3lBczZNdzE1NHplNjZSUTM2cUxoLS13azVpRmdKYkhjS1dWcmQ5VzVMU1dTT3B3S0dVRzg1SDY?oc=5","date":"2023-04-14","type":"deal","source":"BioPharma APAC","summary":"Anika Enters Into Cooperation Agreement with Caligan Partners - BioPharma APAC","headline":"Anika Enters Into Cooperation Agreement with Caligan Partners","sentiment":"neutral"}],"patents":[{"drugName":"Monovisc","drugSlug":"hylan-g-f-20","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":20000000},{"drugName":"Orthovisc","drugSlug":"hylan-g-f-20","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":15000000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Smith & Nephew","Stryker","Zimmer Biomet"],"therapeuticFocus":["Osteoarthritis","Regenerative Medicine"],"financials":{"source":"sec_edgar","revenue":112819000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":112819000,"period":"2025-12-31"},{"value":119907000,"period":"2024-12-31"},{"value":119907000,"period":"2024-12-31"},{"value":166662000,"period":"2023-12-31"},{"value":120792000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":25770000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-10880000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":190270000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.35,"previousClose":14.92,"fiftyTwoWeekHigh":15.4,"fiftyTwoWeekLow":7.87,"fiftyTwoWeekRange":"7.87 - 15.4","fiftyDayAverage":12.39,"twoHundredDayAverage":10.32,"beta":0.28,"enterpriseValue":168706208,"forwardPE":38.4,"priceToBook":1.49,"priceToSales":1.96,"enterpriseToRevenue":1.5,"enterpriseToEbitda":-30.84,"pegRatio":5.94,"ebitda":-5471000,"ebitdaMargin":-4.8,"freeCashflow":13277125,"operatingCashflow":11188000,"totalDebt":26248000,"debtToEquity":18.3,"currentRatio":4.72,"returnOnAssets":-3.5,"returnOnEquity":-6.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":17.5,"targetHighPrice":18,"targetLowPrice":17,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.4,"institutionHeldPercent":93,"sharesOutstanding":13400751,"floatShares":11336365,"sharesShort":712348,"shortRatio":4.94,"shortPercentOfFloat":5.3,"epsTrailing":-0.7,"epsForward":0.4,"revenuePerShare":7.87,"bookValue":10.33,"officers":[{"age":61,"name":"Dr. Cheryl Renee Blanchard Ph.D.","title":"Executive Chair"},{"age":38,"name":"Mr. Stephen D. Griffin","title":"President, Principal Financial Officer, CEO & Director"},{"age":53,"name":"Mr. David  Colleran J.D.","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Mr. Ian W. McLeod","title":"VP, Chief Accounting Officer & Treasurer"},{"age":null,"name":"Mr. Matthew  Hall","title":"Director of Corporate Development & Investor Relations"},{"age":62,"name":"Mr. Mark  Namaroff","title":"Vice President of Investor Relations, ESG & Corporate Communications"},{"age":null,"name":"Mr. James  Chase","title":"Senior Vice President of International Sales & Marketing"},{"age":null,"name":"Mr. Ben  Joseph","title":"Vice President of Commercial & Corporate Development"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.anika.com","phone":"781 457 9000"}}